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A B S T R A C T
Purpose
Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sézary syndrome (SS) are aggressive
lymphomas with a median survival of 1 to 5 years. Clinical management is stage based; however,
there is wide range of outcome within stages. Published prognostic studies in MF/SS have been
single-center trials. Because of the rarity of MF/SS, only a large collaboration would power a study
to identify independent prognostic markers.
Patients and Methods
Literature review identified the following 10 candidate markers: stage, age, sex, cutaneous
histologic features of folliculotropism, CD30 positivity, proliferation index, large-cell transforma-
tion, WBC/lymphocyte count, serum lactate dehydrogenase, and identical T-cell clone in blood and
skin. Data were collected at specialist centers on patients diagnosed with advanced-stage MF/SS
from 2007. Each parameter recorded at diagnosis was tested against overall survival (OS).
Results
Staging data on 1,275 patients with advanced MF/SS from 29 international sites were included for
survival analysis. The median OS was 63 months, with 2- and 5-year survival rates of 77% and
52%, respectively. The median OS for patients with stage IIB disease was 68 months, but patients
diagnosed with stage III disease had slightly improved survival compared with patients with stage
IIB, although patients diagnosed with stage IV disease had significantly worse survival (48 months
for stage IVA and 33 months for stage IVB). Of the 10 variables tested, four (stage IV, age  60
years, large-cell transformation, and increased lactate dehydrogenase) were independent prog-
nostic markers for a worse survival. Combining these four factors in a prognostic index model
identified the following three risk groups across stages with significantly different 5-year survival
rates: low risk (68%), intermediate risk (44%), and high risk (28%).
Conclusion
To our knowledge, this study includes the largest cohort of patients with advanced-stage MF/SS
and identifies markers with independent prognostic value, which, used together in a prognostic
index, may be useful to stratify advanced-stage patients.
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INTRODUCTION
Cutaneous T-cell lymphomas are a family of extranodal lymphomas
of mature T cells presenting in the skin. Mycosis fungoides (MF) is the
most common form, and Sézary syndrome (SS) is a less frequent
erythrodermic variant with leukemic involvement. The revised stag-
ing system from 20071 classifies disease presentation in skin (T),
lymph nodes (N), viscera (M), and blood (B). This TNMB classifica-
tion stratifies patients into those with early-stage (stage IA to IIA) or
advanced stage (stage IIB to IVB) disease (Appendix Table A1, online
only). Early stage carries a good prognosis, with survival often exceed-
ing 10 years.1-3 A third of patients present with advanced skin disease
(T3-4), with median survival times of 35 to 56 months, or nodal
disease (median survival, 13 to 25 months). Involvement of viscera is
rare. Survival according to stage has been reported from centers, with
5-year overall survival (OS) rates of 40% to 65% for stage IIB, 40% to
57% for stage III, 15% to 40% for stage IVA, and 0% to 15% for stage
IVB, whereas at 10 years, up to 40% of stage IIB and III patients were
alive.4 In addition to stage, other potential prognostic markers have
been identified in MF/SS. These include clinical features such as male
sex and older age, elevated lactate dehydrogenase (LDH), and histo-
logic features of folliculotropism (FT) and large-cell transformation
(LCT).5-11 Previous studies of prognostic factors have been mainly
single-center studies, and only a large-scale international collabora-
tion will allow the true impact of these factors to be defined.
A recent study that proposed a prognostic model of MF/SS based
on a large data set (N  1,502) from a single center in the United
Kingdom with a validation set from a single center from the United
States12 prompted the establishment of the Cutaneous Lymphoma
International Consortium (CLIC) consortium. CLIC includes board
members from established cutaneous lymphoma groups, such as the
European Organisation for Research and Treatment of Cancer Cuta-
neous Lymphoma Taskforce, International Society for Cutaneous
Lymphomas, US Cutaneous Lymphoma Consortium, and United
Kingdom Cutaneous Lymphoma Group, and aims to improve under-
standing of the clinical and translational aspects of these rare lympho-
mas through collaborative research, using uniform terminology and
well-defined end points. We report the results of the initial CLIC1
retrospective study designed to test the relevance of candidate prog-
nostic markers on OS in advanced-stage MF/SS. The aim was to
accurately identify patients with a worse outcome who may not be
recognized in the current staging system with the intention of devel-
oping a prognostic index.
PATIENTS AND METHODS
Patient Selection and Staging
Specialist cutaneous T-cell lymphoma centers were contacted through
membershipofthemajorcutaneouslymphomaorganizations(EuropeanOrgani-
sation for Research and Treatment of Cancer, International Society for Cutaneous
Lymphomas, US Cutaneous Lymphoma Consortium, United Kingdom Cutane-
ous Lymphoma Group). This study was approved by a “mother center” institu-
tional review board at Stanford University and also received local approval. Data
were collected retrospectively on consecutive patients from patient records and
existing databases. Eligible patients were those diagnosed with clinical stage IIB or
higherdisease from2007.1 Datawerecollatedfromcentersandreviewedindepen-
dentlyfordataaccuracyandcompletenessatUniversityHospitalBirminghamand
Stanford University. Missing or questionable data were assessed manually, and
queries were resolved with centers.
Prognostic Parameters
After a series of CLIC teleconferences from 2012 to 2013 and literature
review of prognostic markers in MF/SS,4 the following 10 clinical, pathologic,
and laboratory parameters were selected to study: stage, age, sex, histologic
features (obtained from local reports) of FT,2 LCT,13 percentage of CD30
cells within the tumoral component, proliferation index measured by percent-
age of tumoral cells staining positive for Ki-67, WBC/absolute lymphocyte
count (ALC), presence of an identical T-cell receptor clone in blood and skin,
and serum LDH.1 Each parameter was taken from time of initial diagnosis, and
missing data were recorded as not done or not recorded.
Statistical Analysis
Percentage of data fields successfully captured at each site and pooled
collated data were summarized. Actuarial OS and disease-specific survival for
each stage and each prognostic parameter were calculated using the Kaplan-
Meier method. Univariable associations were tested using log-rank tests. Mul-
tivariable analyses were performed using the Cox proportional hazards
regression model. For multivariable analysis, all variables were included in the
model selection process. A backward stepwise approach was taken to select
variables with the most predictive power (P  .10). The proportionality
assumption of the final model was tested using Schoenfeld residuals. Missing
values were included in the model as an additional category because these may
reflect the clinical decision not to perform certain tests. To capture some of the
expected variation between centers, a dummy variable for each was included in
the model but not reported on in this article. Prognostic markers identified
were used in a prognostic model to identify risk groups for advanced MF/SS.
RESULTS
Cohort Characteristics
This study included 1,394 patients from 29 specialist centers
(Europe, n  19; North America, n  7; Oceania, n  1; South
America, n  1; Asia, n  1; Table 1). One thousand two hundred
seventy-five patients (91%) met the eligibility criteria for this study
(stage IIB to IV disease diagnosed from 2007), and these patients were
included in the survival analysis. Data completeness for the other 10
prognostic variables ranged from 36.9% to 99.2% (Table 2). Age and
sex were recorded in 99.2% of patients. The median age of the group
was 63 years (range, 8 to 98 years) with 789 males and 473 females.
Clinical Stage
StageatdiagnosiswasIIBin457,III in320,IVAin463,andIVBin35
patients. The median OS time of the entire group was 63 months with 1-,
2-,and5-yearsurvival ratesof88%,77%,and52%(Table3).Themedian
OS times were 68 months in stage IIB, not reached in stage III, 47.5
months in stage IVA, and 33 months in stage IVB. Predicted 5-year OS
rates are 57.4% for stage IIB, 58.2% for stage III, 42.9% for stage IVA, and
39% for stage IVB. Using stage IIB as a comparator, there was no signifi-
cant difference in survival between stage IIB and stage III, and median OS
wasslightlyimprovedinstageIIIpatients(Fig1).Survivalforpatientswith
stage IVA and IVB disease was significantly worse than that for patients
with stage IIB disease (P  .003 and P  .008, respectively). OS and
disease-specific survival rates, including 1-, 2-, and 5-year predicted sur-
vival according to stage, are listed in Table 3.
Appendix Figure A1 (online only) shows survival according to
blood classification, which was available in 1,215 patients. The revised
staging system for MF/SS (Appendix Table A1) segregates patients
into stages IIIA, IIIB, and IVA1 according to extent of blood involve-
ment (B0, B1, or B2), but compared with stage IIIA, survival differ-
ences for stage IIIB or IVA1 did not reach statistical significance
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(Appendix Fig A2, online only). Stage IVA2 includes patients with
partial or complete effacement of nodal architecture with atypical
lymphocytes (N3). Median survival was 29 months in stage IVA2, with
a 5-year survival rate of 32.9%. In comparison, stage IVA1 had a
median survival time of 53 months and a 5-year predicted survival rate
of 48.3% (P .001; Table 3). Comparing OS across continents and in
patients from the United States versus outside of the United States,
there were no significant differences in survival according to stage.
Prognostic Markers
In univariable analyses, stage IV, age greater than 60 years,
absent FT, LCT in skin, elevated WBC, and elevated LDH were
identified as adverse prognostic factors. Table 2 lists the number of
patients, survival ranges, and probability of survival at 1, 2, and 5
years for each parameter.
Age greater than 60 years (n 813) was associated with a signif-
icantly worse OS (P .001) and a median survival time of 52 months.
Using age  60 years as the reference category, the hazard ratio for
survival was 1.35 (95% CI, 1.04 to 1.75) in patients age 60 to 70 years
and 1.91 (95% CI, 1.48 to 2.45) in patients age70 years. Age was also
significant as a continuous variable (hazard ratio, 1.03; 95% CI, 1.02 to
1.04; P .001), so for every year increase in age, the hazard increased
by 3%. The male-to-female ratio was 1.7:1, with no difference in
survival according to sex.
FT was present in 17.2% of 1,062 FT-evaluable patients. In uni-
variable analysis, those with absent FT in skin had a significantly worse
prognosis than those with FT (P .001). LCT in skin was present in
19.6% of 1,098 LCT-evaluable patients at diagnosis (including 50%
with stage IIB disease). LCT in skin was independently associated with
a worse prognosis (P .003), with an OS of 49.8 months and 5-year
survival of 39%. There was no association between LCT and FT.
CD30 and Ki-67 positivity were intended to be recorded as absolute
percentages, but a number of centers only recorded a range. Percent-
ages of CD30 and Ki-67 positivity of more than 10% and more than
20%, respectively, were considered positive, which allowed most data
to be included. The cutoff is arbitrary because no percentage number
has been agreed upon in MF/SS and varying percentages of positivity
are reported.14 CD30was present in 149 patients (23.3%), and Ki-67
positivity was present in 182 patients (38.6%). No difference in sur-
vival between patients positive or negative for CD30 or Ki-67 was
shown for the cohort, but in T3 disease, both CD30 and Ki-67
positivity were significantly associated with a worse survival (P .001
and P .04, respectively).
Elevated WBC count was associated with a worse prognosis, with
a median survival time of 38 months versus 54 months in patients
without an elevated WBC count (P  .006). Elevated ALC did not
carry a significantly worse prognosis for the whole cohort or those
with T4 disease (P  .358 and P  .4, respectively). Four hundred
fifty-seven patients (62%) had a documented blood clone, and this
was identical to the skin clone in 357 patients (49%). Patients with an
identical blood clone had a worse prognosis, with a median survival of
49.8 months compared with 73.4 months in patients without an
Table 1. Participating International Centers
Center No. Principal Investigator Address No. of Patients
E 001 Julia Scarisbrick University Hospital Birmingham, Birmingham, United Kingdom 35
E 002 Pietro Quaglino University of Turin, Turin, Italy 50
E 004 Sean Whittaker St Thomas’ Hospital, London, United Kingdom 215
E 005 Maarten Vermeer Leiden University Medical Centre, Leiden, the Netherlands 55
E 006 Richard Cowan Christie Hospital, Manchester, United Kingdom 11
E 007 Evangelina Papadavid Athens University Medical School, Athens, Greece 40
E 008 Pablo Oritz-Romero Hospital 12 de Octubre, Madrid, Spain 23
E 009 Martine Bagot Hospital St Louis, Paris, France 50
E 010 Rudolf Stadler Johannes Wesling Medical Centre, Minden, Germany 10
E 011 Robert Gniadecki Bispebjerg Hospital, Copenhagen University, Copenhagen, Denmark 33
E 012 Robert Knobler, Stefanie Pokert University of Vienna Medical School, Vienna, Austria 7
E 018 Nicola Pimpinelli University of Florence, Florence, Italy 22
E 019 Octavio Servietje Hospital Universitari de Bellvitge, Barcelona, Spain 14
E 020 Emilia Hodak Rabin Medical, Tel Aviv, Israel 30
E 021 Alessandro Pileri University of Bologna, Bologna, Italy 14
E 022 Marie Beylot-Barry Centre Hospitalier Universitaire Hospital de Bordeaux, Bordeaux, France 50
E 023 Teresa Estrach Hospital Clinico, University of Barcelona, Barcelona, Spain 13
E 024 Emilio Berti University of Milano, Milano, Italy 29
E 025 Ramon Pujol Hospital del Mar Barcelona, Barcelona, Spain 12
NA 001 Youn Kim Stanford University, Stanford, CA 121
NA 003 Steven Horwitz Memorial Sloan-Kettering Cancer Center, New York, NY 46
NA 004 Joan Guitart Northwestern University, Chicago, IL 46
NA 005 Madeleine Duvic The University of Texas MD Anderson Cancer Center, Houston, TX 164
NA 006 Pierluigi Porcu Ohio State University, Columbus, OH 11
NA 010 Francine Foss Yale University, New Haven, CT 40
NA 011 Alain Rook University of Pennsylvania, Philadelphia, PA 16
OC 001 Miles Prince Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia 56
AS 001 Makoto Sugaya Faculty of Medicine, University of Tokyo, Tokyo, Japan 29
SA 001 José Antonio Sanches University of Sao Paulo Medical School, Sao Paulo, Brazil 33
Abbreviations: AS, Asia; E, Europe; NA, North America; OC, Oceania; SA, South America.
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identical blood clone (P  .086). Serum LDH was elevated in 457
patients (51.1%). An elevated LDH was an adverse risk factor, with a
median survival time of 44.7months compared with 78.8 months in
patients with a normal LDH (P .001).
Prognostic Index Model
In multivariable analysis, stage IV disease (P .009), age greater
than 60 years (P  .001), LCT in the skin (P  .001), and elevated
serum LDH (P .001) were all independent prognostic variables for
worse survival. Using these four variables, we built a prognostic index
model in the subset of patients with a complete data set (N 857; IIB,
n 277; III, n 220; IV, n 360), where zero or one variable equals
low risk, two variables equal intermediate risk, and three to four
variables equal high risk. This model distinguishes risk groups across
stage, with 5-year predicted OS rates of 67.8% (low risk), 43.5%
(intermediate risk), and 27.6% (high risk; P .001, Table 4, and Fig 2).
DISCUSSION
To our knowledge, this study represents the largest reported cohort of
patients with advanced-stage MF/SS (n  1,275). It involves an
unprecedented scale of international collaboration including pa-
tients from 29 centers spanning five continents. The results con-
firm poor survival in patients with advanced MF/SS, with a median
OS of 63 months, 2-year survival of 77%, and 5-year survival of
52%. Using stage IIB as the comparator (median OS, 68 months),
we were unable to fully validate the revised staging; survival in stage
IIIA was in fact slightly improved; the trend in stage IIIB and IVA1
was worse but did not reach statistical significance, whereas OS for
stage IV disease was significantly worse (48 months for stage IVA
and 33 months for stage IVB).
In univariable analyses, six of 10 variables tested were signifi-
cantly associated with a worse survival. These included stage IV, age
greater than 60 years, absent FT in skin, LCT in skin, elevated WBC,
and elevated LDH (Table 2). An identical clone in skin and blood was
associated with a trend toward a worse survival (P .086).
Older age has previously been suggested to be associated with a
worse survival in advanced MF/SS.7,9,10 The mean age of this cohort
was 63 years and was similar across stages. Both age greater than 60
years and greater than 70 years were independent adverse prognostic
markers. Older patients may have compromised OS as a result of
multiple factors including comorbidities and more limited treatment
Table 2. Number of Patients, Survival Ranges, and Probability of Survival With Univariable Analysis for the 10 Parameters Tested
Variable
No. of Patients With
Complete Data (%)
No. of
Patients
OS (months)
RM Survival
(months)
Probability of Survival (%)
PMedian 95% CI IQR 1 Year 2 Years 5 Years
Sex 1,262 (99.0) .937
Male 789 63.0 52.7 to 73.7 25.0-NR 56.2 87.3 76.0 52.1
Female 473 60.3 49.8 to 70.5 26.1-NR 55.8 89.3 77.3 50.4
Age, years 1,265 (99.2)  .001
 60 452 NR NA 34.2-NR 63.6 92.8 84.7 62.5
 60 813 51.0 45.2 to 61.0 21.7-NR 51.7 85.4 71.9 45.6
FT 1,062 (83.3)  .001
Absent 879 57.5 47.7 to 65.4 24.4-NR 54.6 87.9 75.2 49.3
Present 183 NR NA 44.8-NR 65.9 91.4 86.6 66.5
WBC count 716 (56.2) .006
Elevated 252 37.7 30.2 to 50.0 17.8-78.8 44.3 85.8 67.5 35.3
Not elevated 436 54.4 44.4 to 65.4 24.8-NR 53.8 87.9 75.8 46.1
Low 28 57.5 34.4 to NR 34.4-NR 60.0 95.5 84.9 48.8
Absolute lymphocyte count 847 (66.4) .358
Elevated 248 52.7 42.7 to 78.8 24.5-NR 53.5 88.8 76.8 49.5
Not elevated 485 57.3 46.4 to 67.9 23.4-NR 54.7 87.8 74.1 48.4
Low 114 42.2 34.4 to 65.4 18.6-NR 47.4 82.0 72.0 37.8
LDH 894 (70.1)  .001
Elevated 457 44.7 37.5 to 50.5 19.2-NR 48.6 84.6 68.6 39.0
Not elevated 437 78.8 61.2 to NR 33.2-NR 60.5 90.9 81.9 58.4
TCR clone 727 (57.0) .086
Identical clone in blood and skin 357 49.8 44.7 to 69 24.4-NR 53.8 88.4 76.2 45.6
No identical clone in blood and skin 370 73.4 61.0 to NR 30.2-NR 59.3 87.1 78.5 58.7
LCT 1,098 (86.1) .003
Yes 215 49.8 40.3 to 57.3 20.1-NR 48.9 84.8 68.6 38.5
No 883 66.2 61.0 to NR 27.7-NR 57.8 89.3 78.4 54.9
CD30 639 (50.1) .331
Positive  10% 149 55.7 45.4 to NR 22.3-NR 54.9 88.6 74.6 44.9
Positive  10% 490 68.7 60.3 to NR 28.0-NR 58.7 87.8 78.2 56.7
Ki-67 471 (36.9) .552
Positive  20% 182 50.1 44.8 to NR 25.2-NR 55.9 89.3 76.9 46.8
Positive  20% 289 NR 47.2 to NR 30.8-NR 58.7 86.7 78.6 55.6
Abbreviations: FT, folliculotropism; IQR, interquartile range; LCT, large-cell transformation; LDH, lactate dehydrogenase; NR, not reached; OS, overall survival; RM,
restricted mean; TCR, T-cell receptor.
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options. Treatments were not collected in this cohort, and their influ-
ence on outcome cannot be ascertained.
This cohort showed a male predominance, with a male-to-
female ratio of 1.7:1, which is similar to previous reports,3,5,7 but no
difference in survival was shown between sexes. Male sex has been
associated with a worse prognosis in some studies7 but is not a
consistent finding.3,5,9,15
Histologic features of FT, LCT, CD30 positivity, and a high pro-
liferation index may be associated with aggressive disease. FT is re-
ported when atypical lymphocytes are invading the follicular
epithelium. Absent FT may result if the biopsy does not contain a
follicle. Data completeness for FT and LCT was robust ( 80%),
which reflects the ability to record these features on hematoxylin and
eosin–stained slides. FT has been associated with treatment resistance
and worse survival often in the context of early-stage disease. Among
patients with stage IB disease who have FT, survival outcome is similar
to patients with stage IIB disease, and FT may confer a worse prognosis
in patients with LCT.5,7,16-19 Conversely, in this advanced data set, the
presence of FT was associated with a better prognosis in univariable
analysis. However, FT was strongly associated with stage IIB disease
and a younger age (median age, 59 years v 65 years without FT), and
both confer a better prognosis. Moreover, FT was not significant in
multivariable analysis. Other possibilities include that FT is a marker
for progression from stage IB disease to advanced disease or that
therapies in early-stage disease fail to treat FT disease, allowing pro-
gression, whereas patients with advanced disease with FT have sys-
temic therapies capable of treating deep follicular disease.
Alternatively, in early disease, the lack of highly relevant poor prog-
nostic variables found in advanced disease such as elevated LDH and
LCT makes FT significant. Benton et al12 similarly found FT to be a
strong predictor of poor survival in early-stage but not late-stage
patients. Another explanation is that because FT is a skin-only marker,
when one takes into account extracutaneous disease, adverse outcome
of stage IV trumps any risk factor in skin. Further prospective studies
of FT may determine whether this feature is relevant to survival or
treatment response or is a predictor of progression in those with
early-stage disease.
LCT in skin was an independent poor prognostic marker in this
cohort, confirming earlier studies,5,8,9,20 and remained significant in
patients with skin tumors and erythroderma. The definition of LCT of
more than 25% of atypical lymphocytes or clusters of cells having a
diameter of more than four times that of normal lymphocytes has
been widely accepted.13 This definition allows comparisons between
sites, and LCT is likely of prognostic importance. Further studies of
LCT occurring at the time of disease progression and in extracutane-
ous sites such as lymph nodes will be informative.
CD30 and Ki-67 require special stains, and data completeness
was 50% and 37%, respectively. Incomplete data (both not recorded
and not done) may add bias because more thorough investigations
may be associated with aggressive disease. Furthermore, the protocol
stipulated that CD30 and Ki-67 should be recorded as absolute per-
centages (0% to 100%), but many centers had only recorded ranges.
Unlike LCT, CD30 positivity has no standard definition, and variable
reporting may account for conflicting reports in the literature.5,9,21 We
scored CD30 as positive if more than 10% of tumoral cells stained
positively. Although we found a worse OS in CD30patients, this was
not statistically significant for the whole cohort but was associated
with a worse OS in those with skin tumors (T3; P .001).
Table 3.Median Survival and Predicted 1-, 2-, and 5-Year OS Rates According to Stage of MF/SS
Stage
No. of
Patients
OS DSS
Median
(months)
95% CI
(months)
IQR
(months)
RM
(months)
Rate (%)
Median
(months)
95% CI
(months)
IQR
(months)
RM
(months)
Rate (%)
1 Year 2 Years 5 Years 1 Year 2 Years 5 Years
IIB 457 68.37 61.18 to NR 31.0-NR 59.5 88.50 80.10 57.40 NR NA 42.2-NR 66.5 93.10 86.40 67.47
III (all) 320 NR 57.76 to NR 36.8-NR 60.9 89.50 79.50 58.20 NR NA 43.9-NR 65.9 91.77 84.56 66.28
IIIA 187 NR 57.8 to NR 35.2-NR 61.7 89.60 79.80 60.20 NR NA 43.9-NR 66.5 91.95 83..89 68.26
IIIB 119 62.4 44.8 to NR 32.8-NR 58.2 88.50 77.80 55.70 NR NA 44.8-NR 65.4 93.22 86.77 66.12
IVA (all)† 463 47.5 43.0 to 56.10 22.3-NR 50.9 87.60 73.20 42.90 63.4 49.8 to NR 28.4-NR 57.3 91.63 80.03 52.34
IVA1 290 52.7 48.58 to 78.77 31.5-NR 55.7 90.40 79.40 48.30 66.2 50.9 to NR 38.5-NR 60.8 93.41 85.39 55.98
IVA2 127 29 23.7 to 44.4 13.6-68.7 40.4 81.00 59.60 32.90 44.4 27.2 to NR 20.1-NR 48.9 87.27 69.20 44.36
IVB 35 33.3 15.91 to NR 14.0-NR 42.5 78.50 54.30 39.00 33.3 15.9 to NR 4.0-NR 44.1 78.54 54.28 39.04
All stages 1,275 63 55.67 to 69.0 25.4-NR 56.3 88.10 76.60 51.90 NR 68.0 to NR 34.7-NR 62.6 91.79 82.59 61.03
Abbreviations: DSS, disease-specific survival; IQR, interquartile range; MF, mycosis fungoides; NR, not reached; OS, overall survival; RM, restricted mean; SS,
Sézary syndrome.
For 14 patients, data were not available to determine whether stage was IIIA or IIIB.
†For 46 patients, data were not available to determine whether stage was IVA1 or IVA2.
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Fig 1. Kaplan-Meier plot showing survival by stage.
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Ki-67 protein reflects tumor cell proliferation, and a higher
growth fraction is associated with a worse prognosis in multiple
cancers. In our data set, we used a threshold value of 20% Ki-67–
positive cells. No significance in OS was demonstrated for those
with a low or high Ki-67 in the cohort as a whole, but as with
CD30, high Ki-67 was associated with a significantly worse OS in
those with skin tumors (T3; P  .04). Standardized histologic
assessment will be required to determine whether any of these
pathologic features are relevant prognostically.
Blood involvement characterizes SS but may also be seen at lower
levels in classical MF. We found a trend toward a worse survival with
increasing blood involvement, as reflected in OS times in stage IIIA,
IIIB, and IVA1 disease (Appendix Fig A1). Similarly, total ALC is, at
times, used to track peripheral-blood tumor burden. Both elevated
and low ALCs seemed to carry a worse survival than ALC in the
normal range, but neither reached statistical significance. ALCs
greater than 10 109/L may have a poorer prognosis.22,23 This study
confirmed that patients with counts greater than 10  109/L had a
worse prognosis, but this did not reach statistical significance (P 
.066). Elevated WBC, which partially reflects ALC, was significantly
associated with a worse prognosis compared with normal (or low)
WBC in univariable but not multivariable analysis. Other factors that
affect WBC, such as the eosinophil count, have been associated with a
worse prognosis in SS24 and may be relevant to study in future trials.
The presence of an identical clone in skin and blood clone is
classified as a (no clone) or b (clone) alongside blood (B) classification.
The presence of a blood clone does not currently alter stage but
provides a means of recording low-level blood involvement. An iden-
tical blood clone was detected in 49% of patients in this advanced
cohort and was associated with a trend toward a worse survival, with
median survival time of 49.8 months (P .086). An identical blood
clone has been associated with a worse outcome in early-stage MF but
may not be relevant in advanced disease where tumor burden is
already greater.
Forty-nine percent of this cohort had elevated LDH, which was
an independent poor prognostic marker for OS (P .002). Elevated
LDH is associated with a worse survival in a number of lymphomas
and is used in prognostic indices for aggressive follicular and mantle-
cell lymphomas.25-27
Prognostic indices may be developed to stratify patients accord-
ing to survival by combining prognostic factors. A prognostic index
must be simple and reproducible. Prognostic indices are useful when
there is a wide range of survival between stages and a variety of
prognostic variables. MF/SS fits this characterization. Furthermore
treatment in MF/SS is frequently decided on an individual patient
basis with consideration of prognostic factors beyond stage. Four
variables (stage IV, age 60 years, elevated LDH, and LCT in skin)
were independently prognostic for survival in this study. Using these
four variables in a prognostic index model, we identified the following
three risk groups with significantly different survival: low risk (zero to
one variable), intermediate risk (two variables), and high risk (three to
four variables), with 5-year predicted OS rates of 67.8%, 43.5%, and
27.6%, respectively (Table 4, Fig 2). Benton et al12 recently reported
separate cutaneous lymphoma prognostic indices for early-stage (IA
to IIA) and advanced-stage (IIB to IVB) MF/SS. The advanced-stage
index was developed using retrospective data but included a much
smaller number of advanced-stage patients (derivation set, n 445).
Age greater than 60 years was also identified as a significant adverse
prognostic factor in the late-stage model. Male sex carried a poorer
survival but was not found to be important in our data set (P .93).
The other factors included in this index were related to stage (N2/3,
B1/2, and M1). A lack of full data on LDH precluded inclusion.
This study of advanced stages of MF/SS confirms stage IV as a
poor prognostic stage and identifies increasing age, elevated LDH, and
LCT in the skin as independent poor prognostic markers that may be
used together in a prognostic model to identify three risk groups
across stages with significantly different survival (Table 4, Fig 2). This
retrospective study has proven the ability of these international centers
to work together, but the accuracy or consistency of data entry relating
Table 4. Prognostic Index Model Using Four Risk Factors (stage IV, age  60 years, elevated LDH, and LCT in skin)
Risk of Poor Survival
No. of
Patients
No. of
Deaths
Stage (No. of
patients)
1-Year Survival
(months)
2-Year Survival
(months)
5-Year Survival
(months)
Median OS
(months)
Hazard
Ratio 95% CI PIIB III IV
Low (0-1 risk factor) 327 100 166 134 27 94.0 86.6 67.8 NR 1
Intermediate (2 risk
factors) 329 123 91 82 156 83.9 71.9 43.5 46.4 2.09 1.56 to 2.80  .001
High (3-4 risk factors) 201 100 20 4 177 84.7 62.2 27.6 34.2 2.91 2.15 to 3.96  .001
Abbreviations: LCT, large-cell transformation; LDH, lactate dehydrogenase; NR, not reached; OS, overall survival.
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Fig 2. Kaplan-Meier plot showing prognostic index model for low-,
intermediate-, and high-risk groups. Variables included in the prognostic index
model were stage IV, elevated lactate dehydrogenase, age greater than 60 years,
and large-cell transformation in skin (low risk zero to one variable; intermediate
risk  two variables; high risk  three to four variables).
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to the interpretation of pathology reports cannot be confirmed be-
cause no quality assessment of data entry was performed. A prospec-
tive study with consensus criteria, consistently collected data, central
pathologic review, and data monitoring is planned by CLIC to test
these parameters with others and further refine and validate this prog-
nostic index in advanced MF/SS.
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Appendix
Table A1. ISCL/EORTC Revised Staging System for MF/SS
Stage T N† M‡ B§
IA 1 0 0 0, 1
IB 2 0 0 0, 1
IIA 1, 2 1, 2 0 0, 1
IIB 3 0-2 0 0, 1
IIIA 4 0-2 0 0
IIIB 4 0-2 0 1
IVA1 1-4 0-2 0 2
IVA2 1-4 3 0 0-2
IVB 1-4 0-3 1 0-2
Abbreviations: EORTC, European Organisation for Research and Treatment of Cancer; ISCL, International Society for Cutaneous Lymphomas; MF, mycosis
fungoides; SS, Sézary syndrome.
T1, patches or plaques covering  10% of the body surface. Further stratified into T1a (patches only) and T1b (plaque  patch); T2, patches or plaques  10%
of the body surface. Further stratified into T2a (patches only) and T2b (plaque  patch); T3, more than one tumor ( 1 cm); T4, erythroderma, which means
involvement of more than 80% of skin.
†B0, absence of significant blood involvement:  5% of peripheral-blood lymphocytes are atypical (Sézary) cells; B0a, clone negative; B0b, clone positive. B1, low
blood tumor burden: 5% of peripheral-blood lymphocytes are atypical (Sézary) cells but does not meet the criteria of B2; B1a, clone negative; B1b, clone positive.
B2, high blood tumor burden:  1,000/L Sézary cells with positive clone.
‡N0, no palpable lymphadenopathy or histologic evidence of mycosis fungoides. N1, clinically abnormal peripheral lymph nodes and histopathology Dutch grade
1 or National Cancer Institute (NCI) LN0-2. Further stratified into N1a (clone negative) and Nab (clone positive). N2, clinically abnormal peripheral lymph nodes and
histopathology Dutch grade 2 or NCI LN3. Further stratified into N2a (clone negative) and N2b (clone positive). N3, clinically abnormal peripheral lymph nodes and
histopathology Dutch grade 3 or 4 or NCI LN4 (clone positive or negative). Nx, clinically abnormal peripheral lymph nodes but no histologic confirmation.
§M0, no visceral involvement; M1, histologically confirmed visceral involvement.
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Fig A1. Kaplan-Meier plot showing survival according to blood (B) classification.
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Fig A2. Kaplan-Meier plot showing survival by revised staging.
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